From cancer genomics to precision oncology--tissue's still an issue

Cell. 2014 Jun 19;157(7):1509-14. doi: 10.1016/j.cell.2014.05.027.

Abstract

Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel "rationally targeted" cancer therapies.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Genomics
  • Humans
  • Neoplasms / classification
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / pathology*
  • Precision Medicine*

Substances

  • Antineoplastic Agents